Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that its subsidiary Shenyang Haisco Pharmaceutical Co., Ltd. has recently received a "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration. The approval covers the following supplemental applications for cyclopropanfol injection: 1) Dosage and administration for induction and maintenance of general anesthesia in children and adolescents; 2) Revision of safety information in the product labeling.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments